Literature DB >> 32888136

GAB2 and GAB3 are expressed in a tumor stage-, grade- and histotype-dependent manner and are associated with shorter progression-free survival in ovarian cancer.

Caglar Berkel1, Ercan Cacan2.   

Abstract

Ovarian cancer is the most lethal gynecological malignancy and molecular mechanisms of its progression and metastasis are not completely understood. Some members of GAB (GRB2-associated binding) protein family have been reported to be involved in tumor cell proliferation and metastasis in various cancer types. In the present study, we analyzed the expression of GAB proteins (GAB1, GAB2 and GAB3) in ovarian cancer compared to normal ovarian tissue, in terms of tumor stage, tumor grade and histological type. Differential expression analyses performed in R programming environment using multiple transcriptome datasets (n = 1449) showed that GAB1 expression is decreased in ovarian cancer independently of tumor stage, grade and histotype. Unlike GAB1, expression of GAB2 and GAB3 are increased from early stage to late stage and from low grade to high grade in epithelial ovarian cancer. GAB2 and GAB3 also showed histotype-dependent expression. GAB3 was computed as a top gene whose expression most significantly changed between tumor cells from primary tumor, metastases and ascites. High expression of GAB2 and GAB3 was shown to be associated with shorter progression-free survival in ovarian cancer. This study shows that GAB2 and GAB3 can be important regulators of tumor progression and metastasis in ovarian cancer.

Entities:  

Keywords:  Cancer progression; GAB2; GAB3; Metastasis; Ovarian cancer, Transcriptomics

Year:  2020        PMID: 32888136     DOI: 10.1007/s12079-020-00582-3

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  33 in total

1.  A role for the scaffolding adapter GAB2 in breast cancer.

Authors:  Mohamed Bentires-Alj; Susana G Gil; Richard Chan; Zhigang C Wang; Yongping Wang; Naoko Imanaka; Lyndsay N Harris; Andrea Richardson; Benjamin G Neel; Haihua Gu
Journal:  Nat Med       Date:  2005-12-20       Impact factor: 53.440

2.  Histone Deacetylase-1-mediated Suppression of FAS in Chemoresistant Ovarian Cancer Cells.

Authors:  Ercan Cacan
Journal:  Anticancer Res       Date:  2016-06       Impact factor: 2.480

Review 3.  Heterozygous beta thalassaemia with intermediate clinical severity in 9 members of two unrelated families showing vertical transmission.

Authors:  M B Agarwal
Journal:  J Assoc Physicians India       Date:  1987-08

4.  In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.

Authors:  Gavin P Dunn; Hiu Wing Cheung; Pankaj K Agarwalla; Sapana Thomas; Yulia Zektser; Alison M Karst; Jesse S Boehm; Barbara A Weir; Aaron M Berlin; Lihua Zou; Gad Getz; Joyce F Liu; Michelle Hirsch; Francisca Vazquez; David E Root; Rameen Beroukhim; Ronny Drapkin; William C Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-02       Impact factor: 11.205

5.  A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.

Authors:  Tomas Bonome; Douglas A Levine; Joanna Shih; Mike Randonovich; Cindy A Pise-Masison; Faina Bogomolniy; Laurent Ozbun; John Brady; J Carl Barrett; Jeff Boyd; Michael J Birrer
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

6.  Amplification of 11q13 in ovarian carcinoma.

Authors:  Lindsay A Brown; Steve E Kalloger; Melinda A Miller; Ie-Ming Shih; Steven E McKinney; Jennifer L Santos; Ken Swenerton; Paul T Spellman; Joe Gray; C Blake Gilks; David G Huntsman
Journal:  Genes Chromosomes Cancer       Date:  2008-06       Impact factor: 5.006

7.  In silico analysis of DYNLL1 expression in ovarian cancer chemoresistance.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  Cell Biol Int       Date:  2020-03-24       Impact factor: 3.612

8.  MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.

Authors:  Danni Chen; Lei Cao; Xiaojie Wang
Journal:  Oncol Rep       Date:  2019-06-12       Impact factor: 3.906

9.  Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.

Authors:  Ercan Cacan; Mourad W Ali; Nathaniel H Boyd; Shelley B Hooks; Susanna F Greer
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

10.  Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression.

Authors:  C Duckworth; L Zhang; S L Carroll; S P Ethier; H W Cheung
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

View more
  3 in total

1.  Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  Hum Cell       Date:  2021-02-12       Impact factor: 4.174

2.  Lower expression of NINJ1 (Ninjurin 1), a mediator of plasma membrane rupture, is associated with advanced disease and worse prognosis in serous ovarian cancer.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  Immunol Res       Date:  2022-10-03       Impact factor: 4.505

3.  Yay team!: 5.782.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2021-12       Impact factor: 5.782

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.